Literature DB >> 17265769

Protective effect following intranasal exposure of goats to live Pasteurella multocida B:2.

M Zamri-Saad1, Z A Ernie, M Y Sabri.   

Abstract

This study aimed to determine the effect of intranasal exposure to low doses of Pasteurella multocida B:2 on survival of goats challenged with high doses of the same organism. Eighteen goats were selected and divided into three groups. Goats of group 1 were exposed intranasally twice, with a two-week interval, to 7 x 10(6) cfu/ml of live P. multocida B:2. Goats of group 2 were not exposed to P. multocida B:2 but were kept together with the exposed group 1. Goats of group 3 remained as unexposed controls and were kept separated from the other two groups. Serum samples were collected at weekly intervals to determine the antibody levels. At week 5 post exposure, all goats were challenged subcutaneously with 3.7 x 10(10) cfu/ml of live P. multocida B:2. Following challenge exposure, 8 (67%) goats (4 goats from each of groups 1 and 2) were killed owing to haemorrhagic septicaemia. Four goats were killed peracutely within 48 h post challenge, while the other four goats were killed acutely between 2 and 4 days post challenge. None of the goats of group 3 were killed for haemorrhagic septicaemia. Goats of groups 1 and 2 showed significantly (p < 0.05) higher antibody levels following the first intranasal exposure to P. multocida B:2. However, only group 1 retained the significantly (p < 0.05) high antibody levels following a second intranasal exposure, and remained significantly (p < 0.05) higher than groups 2 and 3 at the time of challenge. P. multocida B:2 was successfully isolated from various organs of goats that were killed between 1 and 4 days post challenge.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17265769     DOI: 10.1007/s11250-006-4437-x

Source DB:  PubMed          Journal:  Trop Anim Health Prod        ISSN: 0049-4747            Impact factor:   1.559


  8 in total

1.  Molecular variability among strains of Pasteurella multocida isolated from an outbreak of haemorrhagic septicaemia in India.

Authors:  A Biswas; S B Shivachandra; M K Saxena; A A Kumar; V P Singh; S K Srivastava
Journal:  Vet Res Commun       Date:  2004-05       Impact factor: 2.459

2.  Persistence of the carrier status in haemorrhagic septicaemia (Pasteurella multocida serotype 6:B infection) in buffaloes.

Authors:  M C de Alwis; T G Wijewardana; A I Gomis; A A Vipulasiri
Journal:  Trop Anim Health Prod       Date:  1990-08       Impact factor: 1.559

Review 3.  New perspectives in vaccine development: mucosal immunity to infections.

Authors:  J R McGhee; H Kiyono
Journal:  Infect Agents Dis       Date:  1993-04

Review 4.  Vaccination strategies for mucosal immune responses.

Authors:  P L Ogra; H Faden; R C Welliver
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

5.  Safety, efficacy and cross-protectivity of a live intranasal aerosol haemorrhagic septicaemia vaccine.

Authors:  A Myint; T O Jones; H H Nyunt
Journal:  Vet Rec       Date:  2005-01-08       Impact factor: 2.695

6.  Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination.

Authors:  Y Hirabayashi; H Kurata; H Funato; T Nagamine; C Aizawa; S Tamura; K Shimada; T Kurata
Journal:  Vaccine       Date:  1990-06       Impact factor: 3.641

7.  Characterization of immune response and duration of protection in buffaloes immunized with haemorrhagic septicaemia vaccines.

Authors:  S Chandrasekaran; L Kennett; P C Yeap; N Muniandy; B Rani; T K Mukkur
Journal:  Vet Microbiol       Date:  1994-08-01       Impact factor: 3.293

8.  Development of a clinical syndrome resembling haemorrhagic septicaemia in the buffalo following intravenous inoculation of Pasteurella multocida serotype B:2 endotoxin and the role of tumour necrosis factor-alpha.

Authors:  N U Horadagoda; J C Hodgson; G M Moon; T G Wijewardana; P D Eckersall
Journal:  Res Vet Sci       Date:  2002-06       Impact factor: 2.534

  8 in total
  4 in total

1.  Efficacy of an inactivated recombinant vaccine encoding a fimbrial protein of Pasteurella multocida B:2 against hemorrhagic septicemia in goats.

Authors:  Ina-Salwany Mohd Yasin; Sabri Mohd Yusoff; Zamri-Saad Mohd; Effendy Abd Wahid Mohd
Journal:  Trop Anim Health Prod       Date:  2010-08-10       Impact factor: 1.559

2.  New sites of localisation of Pasteurella multocida B:2 in buffalo surviving experimental haemorrhagic septicaemia.

Authors:  Salleh Annas; Mohammad Zamri-Saad; Faez Firdaus Abdullah Jesse; Zakaria Zunita
Journal:  BMC Vet Res       Date:  2014-04-11       Impact factor: 2.741

3.  Ultrastructural changes in endothelial cells of buffaloes following in-vitro exposure to Pasteurella multocida B:2.

Authors:  Yulianna Puspitasari; Annas Salleh; Mohd Zamri-Saad
Journal:  BMC Vet Res       Date:  2020-06-09       Impact factor: 2.741

Review 4.  Transboundary Animal Diseases, an Overview of 17 Diseases with Potential for Global Spread and Serious Consequences.

Authors:  Elizabeth A Clemmons; Kendra J Alfson; John W Dutton
Journal:  Animals (Basel)       Date:  2021-07-08       Impact factor: 2.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.